🩸 Blood-based biomarker used for the first time to individualise treatment of antibody-mediated rejection after #kidneytransplant ⤵️

Researchers from #MedUniVienna showed that #ddcfDNA can detect transplant injury and identify the need for additional treatment. ⬇️

📰 @lancetrh-europe.bsky.social​

We're looking forward to seeing you at #ISHLT2025! Learn about our 10 abstracts, join our symposia on dd-cfDNA innovations in heart and lung transplantation, and stop by booth # 401 to connect! 📈🤝

ow.ly/H6n350VyYFi

@ishlt.bsky.social #TransplantCare #HeartLung #ddcfDNA #Natera #ISHLT

thanks 🙏 BTS for the invitation!
what a warm welcome to london 🇬🇧

I guess DSA, GEP, ddcfDNA and TTV will nicely come together as comprehensive immune monitoring post SOT

bts.org.uk/bts-autumn-s...

#TTVguide

#CEoT2025 begins tomorrow! Stop by for a SUPER Kidney Plushy at our booth! Feb 27-Mar 1

MORE INFO: www.eurofins-viracor.com/news-and-eve...

🥼 Meet the Scientists
📣 Innovation Theater
🍽️ Educational Dinner (INVITE ONLY)

#TTV #TorqueTeno #ddcfDNA #Cytomegalovirus

📽️ Now on-demand 👉 Check out @natera.com's #ISHLT2026 industry symposium to learn more about how donor-derived cell-free DNA not only rules out rejection with high confidence but also detects broader allograft injury. 💡🫁 🔗 bit.ly/4oBNXck

#ddcfDNA #LungTransplantation #MedSky #TransplantSky

Come see our many Scientific Abstracts this year at #WTC2025.

Full schedule: eurofinstransplant.com/events/eurof...

📌 ABSTRACT - 1663
📌 ABSTRACT - 1633
📌 ABSTRACT - 2768
📌 ABSTRACT - 1688
📌 ABSTRACT - 1655
📌 ABSTRACT - 1628

#WorldTransplantCongress #ddCfDNA #GeneExpression #KidneyTransplant

🧵👇

Check out this #ISHLTVoices podcast episode, presented by #Natera, on the evolution of dd-cfDNA testing and noninvasive rejection monitoring post-heart transplantation. ❤️

🎧 LISTEN NOW at 🔗 bit.ly/4lnW9K2, Spotify, Apple Podcasts 🎧

#HeartTransplantation #ddcfDNA #ProsperaHeart #DQS

🚨 Editor’s Choice 🚨
"On the relative relevance of donor-derived cell-free DNA and urinary chemokines as noninvasive biomarkers for the diagnosis of kidney allograft rejection," by Torres et al
doi.org/10.1016/j.aj...
#KidneyTransplantation #KidneyAllograft #TransplantRejection #Biomarkers #ddcfDNA

🩸 Blood-based biomarker used for the first time to individualise treatment of antibody-mediated rejection after #kidneytransplant ⤵️

Researchers from #MedUniVienna showed that #ddcfDNA can detect transplant injury and identify the need for additional treatment. ⬇️

📰 @lancetrh-europe.bsky.social​

🩸 Blood-based biomarker used for the first time to individualise treatment of antibody-mediated rejection after #kidneytransplant ⤵️

Researchers from #MedUniVienna showed that #ddcfDNA can detect transplant injury and identify the need for additional treatment. ⬇️

📰 @lancetrh-europe.bsky.social​

🩸 Blood-based biomarker used for the first time to individualise treatment of antibody-mediated rejection after #kidneytransplant ⤵️

Researchers from #MedUniVienna showed that #ddcfDNA can detect transplant injury and identify the need for additional treatment. ⬇️

📰 @lancetrh-europe.bsky.social​

CATCH our interview with Daniel Brennan, MD, discussing the KOAR study of dd-cfDNA to predict rejection in kidney transplantation. #nephsky #nephrology #kidneytransplant #ddcfDNA docwirenews.com/post/koar-st...

The #ISHLTv Industry Webinar from #Natera is next week!

⏰ 6 November | 1:00 p.m. ET
🫀 Gain first-hand insights into #ddcfDNA testing + improved outcomes
💸 Free + open to all!
➡️ Sign up at 🔗 https://bit.ly/46Xep7w

Join #Natera on for a one-hour webinar highlighting how the innovations of #ddcfDNA + #DQS improve detection of rejection, reduce reliance on invasive biopsies, & pave the way for more personalized patient management. #HeartTx 🫀📆

Free to register. Learn more at 🔗 https://bit.ly/46Xep7w

#CEoT25 begins next week! Join us for our Innovation Theater, ‘From Injury to Balance: Utilizing #ddcfDNA & TTV in Kidney Transplant to improve long term outcomes,’ presented by Steve Kleiboeker, PhD.

Fri, 28 FEB 2025 | 10:05-10:25pm

INFO: www.eurofins-viracor.com/news-and-eve...

#TTV #NephSky

4/10
1 post, results

⚠️ Infusion reactions in 8/11 in trial arm
⚠️ SAE in 1/11 vs 4/11 in placebo
😃 Resolution of morphologic AMR in 82% vs 20%
📉 MVI score, ddcfDNA, molecular transcripts at 24 weeks
😐 AMR recurrence in 3/9 patients who had resolution with #felzartamab

#NephJC

3/10
1 post, methods

✅Phase 2 double-blind RCT
✅ n= 22 cases of late AMR >180 d post kidney tx
✅ Felzartamab Vs Placebo
✅ Drug dose 16 mg/kg weekly x 4 ➡️ monthly x 5
✅ 1° outcome: safety, AE profile
✅ 2° outcomes: bx results, DSA levels, NK-cell counts, ddcfDNA
#NephJC